Criptococosis Multirresistente asociada con hipertensión intracraneana idiopática. Revisión de la literatura y reporte de un caso
DOI:
https://doi.org/10.46363/jnph.v3i2.2%20Palabras clave:
VIH-SIDA, Meningitis criptocócica, Síndrome inflamatorio de reconstitución inmune, Terapia antirretroviral, Terapia antifúngicaResumen
La criptococosis cerebral es una enfermedad con una prevalencia considerable aun en Latinoamérica, y según la literatura en continente africano, y en menor medida en el resto del mundo. Se trata de una enfermedad micótica asociada principalmente a cuadros de inmunodepresión, lo cual le confiere un alto riesgo de peor pronóstico en estos casos, sobretodo dada un cuadro de inmunosupresión profunda, así como parte del cuadro de síndrome de reconstitución inmune. Esta reportada en la literatura y bien esclarecido el tratamiento de acuerdo a guías actuales de manejo infectológico; sin embargo, existen casos de resistencia al tratamiento aun con los esquemas mencionados. En este artículo haremos la revisión de un caso de criptococosis multirresistente asociada a hipertensión endocraneana refractaria al manejo medico por lo cual se realiza tratamiento con colocación de catéter reservorio tipo Omaya, como parte de un sistema de derivación lumboperitoneal. Se realiza revisión de la literatura y reporte del caso.
Citas
Asawavichienjinda T, Sitthi-Amorn C, Tanyanont V. (1999). Serum cryptococcal antigen: diagnostic value in the diagnosis of AIDS-related cryptococcal meningitis. J Med Assoc Thailand=Chotmaihet Thangphaet; 82(1):65–71.
Bahr NC, Rolfes MA,Musubire A, Nabeta H,Williams DA, Rhein J, et al. (2014). Standardized electrolyte supplementation and fluidmanagement improves survival during amphotericin therapy for cryptococcal meningitis in resource-limited settings. Open Forum Infect Dis, 1(2), ofu070-ofu.
Bicanic T, Meintjes G, Wood R, Hayes M, Rebe K, Bekker LG, et al. (2007). Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviralexperienced patients treated with amphotericin B or fluconazole. Clin Infect Dis Off Publ Infect Dis Soc Am, 45(1):76–80.
Bicanic T, Muzoora C, Brouwer AE, Meintjes G, Longley N, Taseera K, et al. (2009). Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis Off Publ Infect Dis Soc Am; 49(5):702–9.
Boulware D, Rhein.(2012). Prognosis and management of cryptococcal meningitis in patients with human immunodeficiency virus infection. Neurobehav HIV Med; 45.
Boulware DR, Meya DB, Muzoora C, Rolfes MA, Huppler Hullsiek K,Musubire A, et al. (2014). Timing of antiretroviral therapy after diagnosis of cryptococcalmeningitis. N Engl JMed, 370(26), 2487–98. Deferred initiation of ART is associated with improved survival compared to early initiation of ART.
Boulware DR, RolfesMA, RajasinghamR, von HohenbergM, Qin Z, Taseera K, et al. (2014). Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast. Emerg Infect Dis; 20(1): 45–53.
Bozzette SA, Larsen RA, Chiu J, LealMA, Jacobsen J, Rothman P, et al. (1991). A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. New England J Med, 324(9), 580–4.
Carlson RD, Rolfes MA, Birkenkamp KE, Nakasujja N, Rajasingham R, Meya DB, et al.(2014). Predictors of neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study. Metab Brain Dis; 29(2):269–79.
Day JN, Chau TT, Wolbers M, Mai PP, Dung NT, Mai NH, et al. (2013). Combination antifungal therapy for cryptococcal meningitis. N Engl JMed; 368(14):1291–302.
Debruyne D. (1997). Clinical pharmacokinetics of fluconazole in superficial and systemicmycoses. ClinPharmacokinet, 33(1), 52–77.
Govender NP, Patel J, van Wyk M, Chiller TM, Lockhart SR. (2012). Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002-2003 and 2007–2008. Antimicrob Agents Chemother, 55(6), 2606–11.
Jackson AT, Nussbaum JC, Phulusa J, Namarika D, Chikasema M, Kanyemba C, et al. (2012). A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. Aids, 26(11), 1363–70.
Jarvis JN, Boulle A, Loyse A, Bicanic T, Rebe K,Williams A, et al. (2009). High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. Aids; 23(9): 1182–3.
Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS. (2009). Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis; 48(7):856–62.
Jarvis JN, Meintjes G, Rebe K, Williams GN, Bicanic T, Williams A, et al. (2012). Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. Aids, 26(9), 1105–13.
Jarvis JN, Percival A, Bauman S, Pelfrey J, Meintjes G, Williams GN, et al. (2011). Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis Off Publ Infect Dis Soc Am; 53(10):1019–23.
Kabanda T, Siedner MJ, Klausner JD, Muzoora C, Boulware DR. (2014). Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid. Clin Infect Dis; 58(1); 113–6.
Kambugu A, Meya DB, Rhein J, O'Brien M, Janoff EN, Ronald AR, et al. (2008). Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis Off Publ Infect Dis Soc Am;46(11):1694–701.
Khoo SH, Bond J, DenningDW. (1994). Administering amphotericin B-a practical approach. J Antimicrob Chemother, 33(2):203–13.
Kisenge PR, Hawkins AT, Maro VP,McHele JP, Swai NS, Mueller A, et al.(2007). Low CD4 count plus coma predicts cryptococcal meningitis in Tanzania. BMC Infect Dis; 7(1):39.
Krysan DJ. (2014). Toward improved anti-cryptococcal drugs: novel molecules and repurposed drugs. Fungal Genet Biol FG & B.
Kwizera R, Nguna J, Kiragga A, Nakavuma J, Rajasingham R, Boulware DR, et al.(2014). Performance of cryptococcal antigen lateral flow assay using saliva in Ugandans with CD4 <100. PLoS One; 9(7): e103156.
Lewis RJ, Angier MK, Williamson KS, Johnson RD. (2013). Analysis of sertraline in postmortem fluids and tissues in 11 aviation accident victims. J Anal Toxicol, 37(4), 208–16.
Longley N, Muzoora C, Taseera K, Mwesigye J, Rwebembera J, Chakera A, et al. (2008). Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis Off Publ Infect Dis Soc Am, 47(12):1556–61.
Lortholary O, Poizat G, Zeller V, Neuville S, Boibieux A, Alvarez M, et al. (2006). Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS; 20(17): 2183–91.
Lourens A, Jarvis JN, Meintjes G, Samuel CM. (2014). Rapid diagnosis of cryptococcal meningitis by use of lateral flow assay on cerebrospinal fluid samples: influence of the high dose "hook" effect. J Clin Microbiol; 52(12):4172–5.
Loyse A, Bicanic T, Jarvis JN. (2013). Combination antifungal therapy for cryptococcal meningitis. N Engl J Med; 368(26):2522.
Loyse A, Thangaraj H, Easterbrook P, Ford N, Roy M, Chiller T, et al. (2013). Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis;13(7):629–37.
Loyse A, Wilson D, Meintjes G, Jarvis JN, Bicanic T, Bishop L, et al. (2012). Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIVassociated cryptococcal meningitis. Clin Infect Dis Off Publ Infect Dis Soc Am, 54(1), 121–8.
Loyse A,Wainwright H, Jarvis JN, Bicanic T, Rebe K, Meintjes G, et al. (2010). Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. Aids. 2010;24(3):405–10. B, et al. Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS. Aids. 2012;26(16):2110–2.
Magambo KA, Kalluvya SE, Kapoor SW, Seni J, Chofle AA, Fitzgerald DW, et al.(2014). Utility of urine and serum lateral flow assays to determine the prevalence and predictors of cryptococcal antigenemia in HIV-positive outpatients beginning antiretroviral therapy in Mwanza. Tanzania J Int AIDS Soc; 17:19040.
Mdodo R, Moser SA, Jaoko W, Baddley J, Pappas P, Kempf MC, et al. (2011). Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in Kenya. Mycoses, 54(5), e438–42.
Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, Kambugu A, et al. (2010). Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis Off Publ Infect Dis Soc Am; 51(4):448–55.
Muzoora CK, Kabanda T, Ortu G, Ssentamu J, Hearn P, Mwesigye J, et al. (2012). Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. J Infect, 64(1), 76–81.
Pappas PG, Chetchotisakd P, Larsen RA, ManosuthiW, MorrisMI, Anekthananon T, et al. (2009). A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIVassociated cryptococcal meningitis. Clin Infect Dis Off Publ Infect Dis Soc Am, 48(12), 1775–83.
Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. (2009). Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. Aids ;23(4):525–30.
Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. (2010). Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious disease’s society of America. Clin Infect Dis Off Publ Infect Dis Soc Am; 50(3):291–322.
Rajasingham R, RolfesMA, Birkenkamp KE, Meya DB, Boulware DR. (2012). Cryptococcal meningitis treatment strategies in resourcelimited settings: a cost-effectiveness analysis. PLoS Med; 9(9): e1001316.
Rhein J, Bahr NC, Morawski BM, Schutz C, Zhang Y, Finkelman M, et al. 82014). Detection of high cerebrospinal fluid levels of (1->3)- -DGlucan in cryptococcal meningitis. Open Forum Infect Dis; 1(3): ofu105-ofu.
Rhein J, Cloud JL, Hemmert AC, Bahr NC, Bellamkonda S, Oswald C, et al. (2014). Diagnostic performance of a multiplex PCR assay for meningitis in an HIV-infected population in Uganda poster abstract session. Diagn Microbiol Infect Dis; 84(3), 268-273.
Rhein J, Huppler Hullsiek K,Morawski BM, Smith KD, Al-Hadab A,Musubire A, et al. (2015). Adjunctive sertraline for the treatment ofHIVassociated cryptococcal meningitis. Conference on Retroviruses and Opportunistic Infections (CROI); Feb. 26; Seattle, WA2015.
Rothe C, Sloan DJ, Goodson P, Chikafa J, Mukaka M, Denis B, et al. (2013). A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre,Malawi. PloS One, 8(6): e67311.
Saag MS, Cloud GA, Graybill JR, Sobel JD, Tuazon CU, Johnson PC, et al. (1999). A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis, 28(2), 291–6.
Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, et al. (1992). Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med, 26(2):83–9.
Sitapati AM, Kao CL, Cachay ER, Masoumi H, Wallis RS, Mathews WC. (2010). Treatment of HIV-related inflammatory cerebral cryptococcoma with adalimumab. Clin Infect Dis Off Publ Infect Dis Soc Am, 50(2): e7–10.
Sudan A, Livermore J, Howard SJ, Al-Nakeeb Z, Sharp A, Goodwin J, et al. (2013). Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints. Antimicrob Agents Chemother, 57(6), 2793–800.
Temstet A, Roux P, Poirot JL, Ronin O, Dromer F. (1992). Evaluation of a monoclonal antibody-based latex agglutination test for diagnosis of cryptococcosis: comparison with two tests using polyclonal antibodies. J Clin Microbiol; 30(10):2544–50.
Williams DA, Tadeo K, Velamakkani S, Kiggundu R, Meya DB, Rhein J, et al. (2014). Evaluating cryptococcal antigen lateral flow assay by fingerstick whole blood in HIV-infected persons with meningitis. IDweek; Oct. 11, 2014; Philadelphia, PA. Open Forum Infect Dis , 1(1) 2014.
World Health Organization. (2012). Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children 2011 May 31. Available from: http://www.who.int/hiv/pub/cryptococcal_disease2011.
Zhai B, Wu C, Wang L, Sachs MS, Lin X. (2012). The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections. Antimicrob Agents Chemother. 56(7), 3758–66.
Publicado
Número
Sección
Licencia
Derechos de autor 2023 Marcos Isaí Vélez Santillán , Bertin Martinez Silva , Gervith Reyes Soto Reyes Soto, Carlos Castillo Rangel, Bernardo Cacho Díaz, Hugo Santos Benitez
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
